Repository logo
 
Publication

Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximab

2024-05Journal article Open access
Simple item page
dc.contributor.authorSousa, Paula
dc.contributor.authorPatita, Marta
dc.contributor.authorArroja, Bruno
dc.contributor.authorLago, Paula
dc.contributor.authorRosa, Isadora
dc.contributor.authorSousa, Helena Tavares
dc.contributor.authorMinistro, Paula
dc.contributor.authorMocanu, Irina
dc.contributor.authorVieira, Ana
dc.contributor.authorCastela, Joana
dc.contributor.authorMoleiro, Joana
dc.contributor.authorCancela, Eugenia
dc.contributor.authorRoseira, Joana
dc.contributor.authorPortela, Francisco
dc.contributor.authorCorreia, Luis
dc.contributor.authorSantiago, Mafalda
dc.contributor.authorDias, Sandra
dc.contributor.authorAlves, Catarina
dc.contributor.authorAfonso, Joana
dc.contributor.authorDias, Claudia Camila
dc.contributor.authorMagro, Fernando
dc.date.accessioned2024-09-06T09:13:01Z
dc.date.available2024-09-06T09:13:01Z
dc.date.issued2024-05
dc.description.abstractThe emergence of new treatments the inflammatory bowel diseases (IBD) raised questions regarding the role of older agents, namely thiopurines. Aims: To clarify the benefits of combination treatment with thiopurines on Crohn's disease (CD) patients in the maintenance phase of infliximab. Methods: In this analysis of the 2 -year prospective multicentric DIRECT study, patients were assessed in terms of clinical activity, faecal calprotectin (FC), C -reactive protein (CRP), and infliximab pharmacokinetics. A composite outcome based on clinical- and drug -related items was used to define treatment failure. Results: The study included 172 patients; of these, 35.5 % were treated with combination treatment. Overall, 18 % of patients achieved the composite outcome, without statistically significant differences between patients on monotherapy and on combination treatment (21.6% vs 11.5 %, p = 0.098). Median CRP, FC, and infliximab pharmacokinetic parameters were similar in both groups. However, in the sub -analysis by infliximab treatment duration, in patients treated for less than 12 months, the composite outcome was reached in fewer patients in the combination group than in the monotherapy group (7.1% vs 47.1 %, p = 0.021). Conclusion: In CD patients in maintenance treatment with infliximab, combination treatment does not seem to have benefits over infliximab monotherapy beyond 12 months of treatment duration.eng
dc.identifier.doi10.1016/j.dld.2023.10.027
dc.identifier.issn1590-8658
dc.identifier.urihttp://hdl.handle.net/10400.1/25851
dc.language.isoeng
dc.peerreviewedyes
dc.publisherElsevier
dc.relation.ispartofDigestive and Liver Disease
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCombination therapy
dc.subjectInfliximab
dc.subjectMonotherapy
dc.subjectThiopurines
dc.titleThiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximabeng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage743
oaire.citation.issue5
oaire.citation.startPage737
oaire.citation.titleDigestive and Liver Disease
oaire.citation.volume56
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameSousa
person.familyNameRoseira
person.givenNameHelena Tavares
person.givenNameJoana
person.identifier.ciencia-idCF1F-1163-1C4A
person.identifier.orcid0000-0002-6626-205X
person.identifier.orcid0000-0002-5098-8729
relation.isAuthorOfPublication6b1d11dd-486f-4fb3-b41f-02e1cf6a5c2e
relation.isAuthorOfPublication077331f1-402e-455f-8e16-e475d62bc73a
relation.isAuthorOfPublication.latestForDiscovery077331f1-402e-455f-8e16-e475d62bc73a

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1.pdf
Size:
3.54 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ABC2-Artigos (em revistas ou actas indexadas)